Menta Capital’s Indaptus Therapeutics INDP Stock Holding History

Menta Capital’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$229K	Buy	24 +9	+60%	+$114K	0.1%	358
2019 Q1	$248K	Buy	+15	New	+$263K	0.11%	333
2018 Q3	–	Sell	-6	Closed	-$56K	–	622
2018 Q2	$56K	Sell	6 -6	-50%	-$66.5K	0.01%	619
2018 Q1	$171K	Buy	12 +5	+71%	+$70.9K	0.04%	577
2017 Q4	$78K	Buy	+7	New	+$108K	0.02%	609

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Menta Capital's INDP Position: Q2 2019 in Review

Menta Capital increased its Indaptus Therapeutics (INDP) stake by 60% in Q2 2019, buying an estimated $114K and bringing the position to 24 shares worth $229K. The position accounts for 0.1% of the portfolio, ranked #358.

Menta Capital first reported a position in INDP in Q4 2017 and has held it in 5 quarters since. The position peaked at $248K in Q1 2019. 47 funds tracked by Wall St. Rank hold INDP as of Q2 2019.

Menta Capital held 24 shares of Indaptus Therapeutics worth $229K as of Q2 2019.
Menta Capital bought 9 Indaptus Therapeutics shares in Q2 2019, an estimated $114K.
Indaptus Therapeutics made up 0.1% of Menta Capital's portfolio in Q2 2019, its #358 holding.
Menta Capital first reported a position in Indaptus Therapeutics in Q4 2017 and has held it in 5 quarters since.
Menta Capital's Indaptus Therapeutics position peaked at $248K in Q1 2019.
47 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.